ICTUImperial Clinical Trials Unit

Welcome to Imperial Clinical Trials Unit (ICTU)

This website is intended for commercial trial sponsors engaged in the area of pharmaceuticals, medical devices or diagnostic devices

Clinical Trials Search

OR

CurrentAll Trials

REI-EXCISE

Trial Details

  • Trial statusRecruiting
  • Study email contactREI-EXCISE@imperial.ac.uk
  • Chief InvestigatorProf Zoltan Takats and Mr Daniel Leff
  • Project managerDr Ambreen Ashraf
  • SponsorImperial College London
  • Phasen/a

Rapid Evaporative Ionisation Mass Spectrometry for Examination of Circumferential Surgical Excision Margins

Design and Objective

This is a multicentre, prospective, nonrandomised feasibility study, aimed to evaluate the diagnostic accuracy of rapid ionisation mass spectroscopy using an iKnife device. The iKnife will collect vapour, a by-product of surgery, which will pass through the mass spectrometer machine for analysis in order to evaluate what is "normal" and what is "cancerous" breast tissue.

Key inclusion criteria

Patients undergoing breast conserving surgery (BCS) for invasive or non-invasive breast cancer. Inclusion Criteria: • Minimum age 18 (there is no upper age limit) • BCS for ductal carcinoma in situ (B5a) • BCS for invasive ductal carcinoma (B5b) • BCS for invasive lobular carcinoma (B5b) • B3 lesions undergoing surgical excision

Study Disclaimer Statement

Funded by Cancer Research UK